NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Featured Updates to the NCCN Guidelines®
Search for other papers by Shaji K. Kumar in
Current site
Google Scholar
PubMed
Search for other papers by Natalie S. Callander in
Current site
Google Scholar
PubMed
Search for other papers by Kehinde Adekola in
Current site
Google Scholar
PubMed
Search for other papers by Larry D. Anderson Jr in
Current site
Google Scholar
PubMed
Search for other papers by Muhamed Baljevic in
Current site
Google Scholar
PubMed
Search for other papers by Rachid Baz in
Current site
Google Scholar
PubMed
Search for other papers by Erica Campagnaro in
Current site
Google Scholar
PubMed
Search for other papers by Caitlin Costello in
Current site
Google Scholar
PubMed
Search for other papers by Christopher D’Angelo in
Current site
Google Scholar
PubMed
Search for other papers by Benjamin Derman in
Current site
Google Scholar
PubMed
Search for other papers by Srinivas Devarakonda in
Current site
Google Scholar
PubMed
Search for other papers by Noura Elsedawy in
Current site
Google Scholar
PubMed
Search for other papers by Amandeep Godara in
Current site
Google Scholar
PubMed
Search for other papers by Kelly Godby in
Current site
Google Scholar
PubMed
Search for other papers by Jens Hillengass in
Current site
Google Scholar
PubMed
Search for other papers by Leona Holmberg in
Current site
Google Scholar
PubMed
Search for other papers by Myo Htut in
Current site
Google Scholar
PubMed
Search for other papers by Carol Ann Huff in
Current site
Google Scholar
PubMed
Search for other papers by Malin Hultcrantz in
Current site
Google Scholar
PubMed
Search for other papers by Yubin Kang in
Current site
Google Scholar
PubMed
Search for other papers by Sarah Larson in
Current site
Google Scholar
PubMed
Search for other papers by Hans C. Lee in
Current site
Google Scholar
PubMed
Search for other papers by Michaela Liedtke in
Current site
Google Scholar
PubMed
Search for other papers by Thomas Martin in
Current site
Google Scholar
PubMed
Search for other papers by James Omel in
Current site
Google Scholar
PubMed
Search for other papers by Timothy Robinson in
Current site
Google Scholar
PubMed
Search for other papers by Aaron Rosenberg in
Current site
Google Scholar
PubMed
Search for other papers by Mark A. Schroeder in
Current site
Google Scholar
PubMed
Search for other papers by Daniel Sherbenou in
Current site
Google Scholar
PubMed
Search for other papers by Attaya Suvannasankha in
Current site
Google Scholar
PubMed
Search for other papers by Jason Valent in
Current site
Google Scholar
PubMed
Search for other papers by Asya Nina Varshavsky-Yanovsky in
Current site
Google Scholar
PubMed
Search for other papers by Dan Vogl in
Current site
Google Scholar
PubMed
Search for other papers by Emily Kovach in
Current site
Google Scholar
PubMed
Search for other papers by Rashmi Kumar in
Current site
Google Scholar
PubMed
The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.
Provided content development and/or authorship assistance.
Shaji K. Kumar, Natalie S. Callander, Muhamed Baljevic, Emily Kovach, and Rashmi Kumar
The full and most current version of these NCCN Guidelines is available at NCCN.org.
NCCN CATEGORIES OF EVIDENCE AND CONSENSUS
Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus (≥50%, but <85% support of the Panel) that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise indicated.
NCCN CATEGORIES OF PREFERENCE
Preferred intervention: Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
Other recommended intervention: Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.
Useful in certain circumstances: Other interventions that may be used for selected patient populations (defined with recommendation).
All recommendations are considered appropriate.
NCCN recognizes the importance of clinical trials and encourages participation when applicable and available. Trials should be designed to maximize inclusiveness and broad representative enrollment.
PLEASE NOTE
The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment.
The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel’s discussion, including the literature reviewed.
The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their application or use in any way.
© 2019-2024 National Comprehensive Cancer Network